Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clementia Pharmaceuticals Inc.

Division of Ipsen
www.clementiapharma.com

Latest From Clementia Pharmaceuticals Inc.

Blow To Ipsen As FerGene Nabs CEO Meek

The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.

Appointments Leadership

Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

Clinical Trials Safety

Ipsen CBO: We Are Seeking Fresh Rare Disease Buys

Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.

Commercial Companies

Ipsen Doubles Down On FOP With Blueprint Pact

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

Companies Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • Clarissa Desjardins, PhD, CEO
    Steve Forte, CFO
    Donna Grogan, MD, CMO
    Jeff Packman, Chief Dev. Officer
  • Contact Info
  • Clementia Pharmaceuticals Inc.
    Phone: (514) 940-3600
    1000 de la Gauchetière O
    Ste. 1200
    Montreal, H3B 4W5
    Canada
UsernamePublicRestriction

Register